valbenazine (Neurocrine Biosciences)

MT-5199 is Mitsubishi Tanabe Pharma's development code for **valbenazine**, an oral small-molecule vesicular monoamine transporter 2 inhibitor used for the treatment of tardive dyskinesia. The provided clinical trial record identifies MT-5199 in the J-KINECT study and lists the intervention as valbenazine, directly linking the code to this active ingredient. Mitsubishi Tanabe Pharma developed and commercialized the product in Japan and other select Asian markets under license from Neurocrine Biosciences, launching it in Japan in 2022 as DYSVAL for tardive dyskinesia; other select Asian market branding includes REMLEAS.

Brand names

DYSVALREMLEAS

Other names

valbenazine